Keros Therapeutics (KROS) Competitors $15.78 +0.61 (+4.01%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS vs. RXRX, TARS, BLTE, OCUL, IDYA, AGIO, HRMY, DNLI, IRON, and MESOShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Recursion Pharmaceuticals (RXRX), Tarsus Pharmaceuticals (TARS), Belite Bio (BLTE), Ocular Therapeutix (OCUL), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), Harmony Biosciences (HRMY), Denali Therapeutics (DNLI), Disc Medicine (IRON), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. Keros Therapeutics vs. Its Competitors Recursion Pharmaceuticals Tarsus Pharmaceuticals Belite Bio Ocular Therapeutix IDEAYA Biosciences Agios Pharmaceuticals Harmony Biosciences Denali Therapeutics Disc Medicine Mesoblast Recursion Pharmaceuticals (NASDAQ:RXRX) and Keros Therapeutics (NASDAQ:KROS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability. Do analysts rate RXRX or KROS? Recursion Pharmaceuticals currently has a consensus target price of $7.00, suggesting a potential upside of 39.86%. Keros Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 90.13%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Keros Therapeutics is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recursion Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Keros Therapeutics 0 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals & insiders have more ownership in RXRX or KROS? 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 8.4% of Recursion Pharmaceuticals shares are held by company insiders. Comparatively, 20.6% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is RXRX or KROS more profitable? Keros Therapeutics has a net margin of 8.06% compared to Recursion Pharmaceuticals' net margin of -1,004.91%. Keros Therapeutics' return on equity of 2.96% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Recursion Pharmaceuticals-1,004.91% -76.09% -54.29% Keros Therapeutics 8.06%2.96%2.74% Which has more volatility and risk, RXRX or KROS? Recursion Pharmaceuticals has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Does the media prefer RXRX or KROS? In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Keros Therapeutics. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 10 mentions for Keros Therapeutics. Keros Therapeutics' average media sentiment score of 0.96 beat Recursion Pharmaceuticals' score of 0.88 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Keros Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, RXRX or KROS? Keros Therapeutics has lower revenue, but higher earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecursion Pharmaceuticals$58.84M36.93-$463.66M-$1.78-2.81Keros Therapeutics$3.55M180.55-$187.35M$0.3150.90 SummaryKeros Therapeutics beats Recursion Pharmaceuticals on 13 of the 16 factors compared between the two stocks. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$638.83M$3.09B$5.82B$9.75BDividend YieldN/A2.23%3.84%4.09%P/E Ratio50.7321.0131.1425.96Price / Sales180.55396.98475.48122.90Price / CashN/A43.0937.1558.38Price / Book0.918.069.116.38Net Income-$187.35M-$54.72M$3.26B$265.56M7 Day Performance8.97%2.30%1.94%1.81%1 Month Performance14.92%7.21%4.91%1.14%1 Year Performance-64.73%12.85%31.21%20.98% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics3.0458 of 5 stars$15.78+4.0%$30.00+90.1%-67.7%$638.83M$3.55M50.73100News CoverageRXRXRecursion Pharmaceuticals2.6216 of 5 stars$5.62-1.5%$7.00+24.7%-37.3%$2.28B$64.51M-3.15400Insider TradeTARSTarsus Pharmaceuticals1.9359 of 5 stars$53.04+0.6%$66.67+25.7%+116.9%$2.24B$295.52M-22.7650News CoveragePositive NewsBLTEBelite Bio2.5894 of 5 stars$69.60-2.7%$96.67+38.9%+32.5%$2.22BN/A-44.9010OCULOcular Therapeutix3.9475 of 5 stars$12.62+0.9%$17.20+36.3%+31.4%$2.19B$63.72M-9.86230IDYAIDEAYA Biosciences4.519 of 5 stars$24.40-0.1%$48.09+97.1%-38.0%$2.14B$7M-6.4480Positive NewsAGIOAgios Pharmaceuticals4.3317 of 5 stars$36.65+0.1%$56.33+53.7%-18.9%$2.13B$36.50M3.33390HRMYHarmony Biosciences4.5893 of 5 stars$36.57-0.3%$51.00+39.5%+1.3%$2.11B$714.73M11.81200Positive NewsDNLIDenali Therapeutics4.1632 of 5 stars$14.38-2.9%$33.85+135.4%-39.1%$2.10B$330.53M-5.14430News CoverageIRONDisc Medicine3.4812 of 5 stars$60.56-0.9%$95.73+58.1%+21.2%$2.10BN/A-13.5530MESOMesoblast2.1102 of 5 stars$15.97+5.1%$18.00+12.7%+133.0%$2.04B$5.90M0.0080News CoverageUpcoming Earnings Related Companies and Tools Related Companies Recursion Pharmaceuticals Alternatives Tarsus Pharmaceuticals Alternatives Belite Bio Alternatives Ocular Therapeutix Alternatives IDEAYA Biosciences Alternatives Agios Pharmaceuticals Alternatives Harmony Biosciences Alternatives Denali Therapeutics Alternatives Disc Medicine Alternatives Mesoblast Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KROS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.